Menu visibility control

Video

Events

Startup Surgery

Most Recent

Government & Policy

Here’s how UK tech reacted to the Supreme Court’s Brexit ruling

Investments

Wiltshire-based HealthTech firm Atlas Genetics closes $35m Series D

Investments

Leeds-based online sports network Pitchero lands £3.1m Series A

Press Releases

Starling Bank first of digital challengers to join Faster Payments as direct partner
No more electronic ‘loose change’: innovative fintech charity payment scheme launched today across 6,000 UK schools
Chimni calls for the UK proptech community to work more closely with the housebuilding industry

Life science firms turning to crowdfunding for finance

Life Science
twitterlinkedinFacebookgoogle_plustwitterlinkedinFacebookgoogle_plus

European life sciences companies are increasingly using equity crowdfunding to finance their growth, a new report from market analyst BIOCOM AG has revealed.

The report titled “Analysis of Crowd-based Financing in European Life Sciences” found that UK equity crowdfunding platform SyndicateRoom leads the way when it comes to life science fundraising.

Since its launch two years ago SyndicateRoom has completed 16 life science raises across Europe.

Crowdfunding: what it is and how it works

The found that since 2010, crowdfunding platforms have raised £17m across Europe for 42 life science businesses, with an average raise of around £400K.

Most of this momentum has been in recent years, with nine raises in 2013, 18 raises in 2014 and 13 in the first half of 2015.

SyndicateRoom alone accounts for almost 40% of those raises.

Report author Sandra Wirsching said: “With respect to the high capital demand in the life sciences, it was only a question of time before firms jumped on the bandwagon of crowd financing.

“It is considered as a marketing tool and add-on to other financing instruments.”

“British crowdfunding platforms are amongst the most experienced in Europe. This is mostly due to Britain’s favourable regulatory framework that supports investment in higher-risk technology companies. Furthermore, platforms with strong ties to professional investors, such as SyndicateRoom, fit best to the high capital demand of life science companies.”

SyndicateRoom CEO Gonçalo de Vasconcelos added: “Our unique investor-led model allows our members to co-invest alongside experienced angel investors in highly sophisticated investment opportunities on the same economic terms as the lead investors.

“This is a powerful and successful model for life sciences businesses as they raise capital, as well as a range of other industries, including pharmaceuticals, information technology, property and even movie making.

“We’re particularly proud to lead Europe in life sciences, against a field that includes specialist life sciences platforms. This is a testament to the strength of our model, uniting the crowd with professional investors that often have deep, sector-specific expertise.”

The full BIOCOM report is available here.

 

Enter your e-mail address to receive updates straight to your inbox

* indicates required
Send me news on...
twitterlinkedinFacebookgoogle_plustwitterlinkedinFacebookgoogle_plus

Editor's picks

Supreme Court

Here’s how UK tech reacted to the Supreme Court’s Brexit ruling
posted 5 hours ago

HealthTech

Wiltshire-based HealthTech firm Atlas Genetics closes $35m Series D
posted 7 hours ago

pitchero

Leeds-based online sports network Pitchero lands £3.1m Series A
posted on January 23, 2017

PM Theresa May

UK tech community reacts to Theresa May’s Industrial Strategy proposals
posted on January 23, 2017

Theresa May

PM Theresa May to reveal Industrial Strategy Challenge Fund to support UK tech
posted on January 23, 2017

Tech for good

Here’s how tech for good startups can maximise their chances of getting funded
posted on January 23, 2017